's Chart of the Day - Cytokinetics
Related Stocks
 CYTK - Cytokinetics

The Barchart Chart of the Day belongs to the biopharmaceutical company Cytokinetics (CYTK). I found the stock by sorting Barchart's Top 100 Stocksfirst by the most frequent number of new highs in the last month, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 8/16 the stock gained 1.51%.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.


Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 105.15+ Weighted Alpha
  • 81.88% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 11 new highs and up 15.74% gain in the last month
  • Relative Strength Index 59.38%
  • Technical support level at 13.23
  • Recently traded at 13.46 with a 50 day moving average of 11.84

Fundamental factors:

  • Market Cap $818 million
  • Revenue expected to grow .70% this year and another .40% next year
  • Earnings estimated to compound at an annual rate of 15.00% for the next 5 years
  • Wall Street analysts issued 1 strong buy and 7 buy recommendations on the stock
  • The individual investors following the stock on Motley Fool voted 163 to 18 that the stock will beat the market
  • 6,863 investors are monitoring the stock on Seeking Alpha